Summit Therapeutics
Generated by Meeveem AI
"Developing breakthrough bispecific antibodies to resolve serious unmet needs in oncology"
Miami, FL
•251 - 500 Employees
•Biotechnology
About Summit Therapeutics
Summit Therapeutics is a biopharmaceutical oncology company advancing ivonescimab, a novel bispecific antibody combining PD-1 blockade with anti-angiogenesis effects. The company resolves serious unmet medical needs for cancer patients through therapies designed to improve quality of life and increase duration of life for patients, physicians, caregivers, and society. With operations in Miami, Palo Alto, Princeton, Oxford, and Dublin, Summit executes Phase III trials including HARMONi studies in non-small cell lung cancer. The leadership team, responsible for the 21 billion dollar Pharmacyclics sale, applies proven expertise to rapid trial enrollment and commercialization strategies.
265
Team Members
2003
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where cancer patients access breakthrough therapies that meaningfully extend life with dignity, where oncology innovation reaches those with serious unmet needs, transforming cancer from a terminal diagnosis into a manageable condition.
Our Mission
Summit Therapeutics exists to resolve serious, unmet medical needs for the betterment of overall human health by developing and commercializing patient friendly medicinal therapies that improve quality of life and increase potential duration of life.